Clinical trial · Interventional
Why do Oral Contraceptives Prevent Ovarian Cancer?
Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Use of oral contraceptives (OCs) reduces a woman's risk of ovarian cancer very significantly and the protective effect continues for at least 25 years after use of OCs is stopped; the mechanisms of how this occurs are not understood. We are proposing here to directly study the effect of OCs on the fallopian tube and inclusion cysts within the ovary - sites from which most ovarian cancers are thought to arise - in order to better understand the mechanistic basis for OC protection against ovarian cancer. We think the protection results from reduced cell proliferation. It will lay the foundation for further studies to ensure that the protection against ovarian cancer afforded by 'traditional' OCs is not lost with alterations in OC formulation, and, if possible, to guide development of OC formations to improve further on the protection afforded by OCs.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Fimbriae | — | UNRESOLVED | — |
| Ovarian Cancer Risk | — | UNRESOLVED | — |
| Ovarian Cortical Inclusion Cysts | — | UNRESOLVED | — |
| Risk-reducing Surgery | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OrthoNovum 1/35 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- No intervention
- description
- No intervention.
- type
- ACTIVE_COMPARATOR
- label
- OrthoNovum 1/35
- description
- OrthoNovum 1/35
- interventionNames
- Drug: OrthoNovum 1/35
Primary outcomes (1)
- measure
- Differences in cell proliferation as measured by Ki67 immunohistochemical analysis in the fallopian tube fimbriae of women on the OC arm compared to women on the no treatment arm.
- timeFrame
- Cell proliferation (Ki67) will be measured in the specimen that is removed as part of the patients surgery (the surgery is not a study procedure).
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Premenopausal * 30 and 45 years of age * Scheduled to undergo a laproscopically conducted RR-BSO, risk reducing salpingectomy, salpingectomy for sterilization, or salpingectomy with hysterectomy for non-cancer related conditions * Have at least one ovary Exclusion Criteria: * Past hysterectomy * Past diagnosis of ovarian cancer * Use of Tamoxifen, Raloxifene or hormone replacement therapy in the past 3 months * Use of Chemotherapy in the last 6 months
References
Publications (0)
Data not yet available